AMPE Ampio Pharmaceuticals, Inc.

-0.0407  -5%
Previous Close 0.80
Open 0.77
Price To book 9.11
Market Cap 43.55M
Shares 57,242,000
Volume 205,588
Short Ratio 23.83
Av. Daily Volume 335,311

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

STRIDE study mid April 2015 did not meet endpoint. Second Phase 3 trial also did not meet primary endpoint - June 2016. Further pre-approval trial required - initiation announced May 1, 2017.
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Diabetic Macula Edema

Latest News

  1. Ampion™ Human Macrophage Study Results Accepted for Presentation at the 2017 Annual AAST Meeting in Baltimore
  2. Ampio Initiates Pivotal Trial of Ampion™
  3. The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Ampio Pharmaceuticals, Inc. -- AMPE
  4. Ampio Pharmaceuticals Amends Warrant Agreement
  5. Colorado biotech's accountants express 'substantial doubt' about firm's future
  6. Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™
  7. Update - Ampio Pharmaceuticals Provides Corporate Update
  8. Ampio Pharmaceuticals Provides Corporate Update
  9. Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST
  10. Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee
  11. Ampio Updates Regulatory Status of AMPION™
  12. 7 Stocks Under $10 That Could Make You a Lot of Money
  13. Ampio Hosting Conference Call Today, July 5, 4:30pm ET
  14. Answering Two Most Important Questions Surrounding Ampio Pharmaceuticals Inc (AMPE)
  15. 4 Companies That Destroyed Shareholders Despite a Brexit Recovery
  16. Why Ampio Pharma (AMPE) Stock Is Plummeting Today
  17. Ampio Crashes After Late-Stage Trial Failure
  18. Ampio announces results of Ampion™ trials